Astellas Pharma (OTCMKTS:ALPMY) Sees Unusually-High Trading Volume – Should You Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw unusually-high trading volume on Friday . Approximately 294,592 shares traded hands during mid-day trading, an increase of 116% from the previous session’s volume of 136,389 shares.The stock last traded at $16.44 and had previously closed at $16.09.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ALPMY shares. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 19th. Smbc Nikko Sec. upgraded shares of Astellas Pharma to a “hold” rating in a research report on Monday, February 16th. Four analysts have rated the stock with a Hold rating, According to MarketBeat, Astellas Pharma currently has a consensus rating of “Hold”.

Astellas Pharma Trading Up 2.2%

The company has a 50 day moving average of $14.61 and a 200 day moving average of $12.61. The firm has a market cap of $29.77 billion, a P/E ratio of 13.82 and a beta of 0.18. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09.

Astellas Pharma (OTCMKTS:ALPMY) last posted its earnings results on Wednesday, February 4th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.15. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.21 billion. Astellas Pharma had a net margin of 15.63% and a return on equity of 23.62%. Analysts predict that Astellas Pharma Inc. will post 0.42 EPS for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).